Journey Medical Corp (DERM) - News Archive

Showing 4 of 4 results.

Transformative Milestones in Dermatology FDA Approves Journey Medical’s Emrosi for Rosacea Management,

Revolutionizing Rosacea Treatment: Journey Medical Corporation s Emrosi Receives FDA ApprovalIn a significant advancement for dermatological therapeutics, Journey Medical Corporation has announced that the U.S. Food and...

Nov 4, 2024 • Major Pharmaceutical Preparations Industry Product Service News DFD-29

Augmenting Dermatology: Journey Medical Corporation's DFD-29 Shows Promise in Impacting Healthy Adults' Microbial Flora

Journey Medical Corporation recently announced the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This significant mi...

Mar 11, 2024 • Major Pharmaceutical Preparations Industry Clinical Study Dermatology

DFD-29: The Future of Rosacea Treatment Glimmers Bright as Journey Medical Corporation Seeks FDA approval.

Journey Medical Corporation has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DFD-29, potentially heralding a breakthrough triumph in the treatment of Rosacea. If app...

Jan 5, 2024 Product Service News New Drug Application

Journey Medical's $20 Million Credit Facility Expands Horizons, Paves the Way for DFD-29's Revolutionary Dermatology Breakthrough

Journey Medical Corporation Secures Credit Facility from SWK Holdings, Opening Doors for Future Growth and InnovationIn an exciting development for Journey Medical Corporation, the company has successfully secured a cre...

Jan 2, 2024 Financing Agreement Credit Facility